{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-025295","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.417752+00:00","generated_at":"2026-05-18T08:50:51.018401+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galectin Therapeutics secures $10M line of credit from Chairman Uihlein; extends existing debt to Sept 2026","bullets":["Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.","Interest at Applicable Federal Rate (currently 4.05%) plus 2%; conversion price floor $3.00 per share.","Up to 200,000 warrants issued ratably; exercise price 150% of closing price, capped at $10, floor $3.","Company extends existing $81M in convertible notes & lines of credit to September 30, 2026.","Board approves $100K retention bonuses for CMO Dr. Khurram Jamil & CFO Jack Callicutt; partnership bonus if belapectin deal by Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-025295","json":"https://secwatch.observer/filing/0001140361-25-025295.json","markdown":"https://secwatch.observer/filing/0001140361-25-025295.md","text":"https://secwatch.observer/filing/0001140361-25-025295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/0001140361-25-025295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/ef20051584_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:50:51.018401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}